Walleye Capital
AGIO icon

Walleye Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Walleye Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-150,511
Closed -$4.41M – 4446
2025
Q1 		$4.41M Sell
150,511
-49,027
-25% -$1.63M 0.02% 864
2024
Q4 		$6.56M Buy
199,538
+55,518
+39% +$2.61M 0.02% 900
2024
Q3 		$6.4M Buy
144,020
+124,110
+623% +$5.64M 0.01% 997
2024
Q2 		$859K Sell
19,910
-126,417
-86% -$4.56M ﹤0.01% 3008
2024
Q1 		$4.28M Sell
146,327
-190,135
-57% -$5.09M 0.01% 1412
2023
Q4 		$7.49M Buy
+336,462
New +$7.54M 0.02% 843
2022
Q4 		– Sell
-85,629
Closed -$2.42M – 3139
2022
Q3 		$2.42M Buy
+85,629
New +$2.3M 0.05% 456
2019
Q4 		– Sell
-10,200
Closed -$386K – 1739
2019
Q3 		$331K Buy
+10,200
New +$422K 0.02% 945
2019
Q2 		– Sell
-354
Closed -$18.9K – 1687
2019
Q1 		$24K Buy
+354
New +$20.6K ﹤0.01% 1326

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Walleye Capital's AGIO Position: Q2 2025 in Review

Walleye Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 150,511 shares — an estimated $4.41M sold.

Walleye Capital first reported a position in AGIO in Q1 2019 and held it in 9 quarters. The position peaked at $7.49M in Q4 2023. 215 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

  • Walleye Capital reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 150,511 Agios Pharmaceuticals shares in Q2 2025, an estimated $4.41M.
  • Walleye Capital first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Walleye Capital's Agios Pharmaceuticals position peaked at $7.49M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.